Dr. Elizabeth Pavez Lorie: Why 90% of Treatments Fail | Stories in Life Sciences

90% of drugs fail in clinical trials. In this episode of Stories in Life Sciences by MedAxis AI, Christopher Wilson sits down with Dr. Elizabeth Pavez Lorie, CEO and Co-founder of CompreVie, to explore why that number keeps climbing and what biotech innovation can do about it.Dr. Lorie is building human-relevant organ and tissue models that move, react, and respond like the human body, no animal models required. Her work sits at the intersection of AI-powered drug discovery, digital health, and clinical research, and she's doing it as a founder navigating the biotech funding downturn while generating early revenue through pilot testing.In this episode of Stories in Life Sciences, we cover:* Why 90% of drugs fail in clinical trials and what that means for pharma R&D* How human-relevant testing models are replacing animal models in drug development* CompreVie's approach to building advanced organ and tissue models for biotech startups* The path from academia to entrepreneurship in life sciences* Fundraising strategy and generating early revenue in the biotech funding downturn* The future of AI in healthcare, clinical research innovation, and medtechWho this is for: founders, investors, and researchers in biotech, medtech, digital health, and pharmaceutical R&D who want to understand where human-centered testing is headed.Guest:Dr. Elizabeth Pavez Lorie, CEO and Co-founder, CompreViewww.comprevie.comhttps://www.linkedin.com/company/comprevieHost:Christopher Wilson, Founder, MedAxis AIwww.medaxisai.orghttps://www.linkedin.com/in/christopher-wilson-medaxisaihttps://www.linkedin.com/company/medaxisaiFollow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.